CGTX - Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference | Benzinga
PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi, will present at the 23rd Annual Needham Virtual Healthcare Conference taking place April 8-11, 2024. During her presentation, Ms. Ricciardi will review recent corporate accomplishments and anticipated clinical milestones.
Details of Cognition's presentation are as follows:
Event: Annual Needham Virtual Healthcare Conference
Date/Time: Thursday, April 11, 2024 at 8:00 a.m. Eastern Time
Webcast: https://wsw.com/webcast/needham138/cgtx/2268084
A live webcast of the presentation will be available on the "events and presentations" section of Cognition's investor relations site, and an archived replay will be available for playback 90 days following the event.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of ?-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the ?-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be ...